Altamira Therapeutics (NASDAQ: CYTO) stock soared over 35% on Monday after the company partnered with Univercells Group to explore mRNA vaccine delivery.
Altamira Therapeutics (CYTO) has partnered with Univercells Group to evaluate the efficacy of its proprietary SemaPhore platform in mRNA vaccine delivery.
Under the terms of the agreement, Univercells will conduct experiments involving a proprietary mRNA vaccine delivered through Altamira’s SemaPhore nanoparticle platform. If these experiments yield favorable outcomes, both companies plan to discuss and negotiate a commercial agreement for developing and manufacturing nanoparticle-based mRNA vaccines utilizing Univercells’ production platform.
Covadonga Pañeda, Ph.D., Altamira’s Chief Operating Officer, expressed enthusiasm regarding the collaboration with Univercells, emphasizing the potential of SemaPhore as a delivery vehicle for mRNA vaccines.
She noted,
“SemaPhore has shown to be an efficient delivery vehicle for therapeutic RNA in many different disease models. With this collaboration, we will explore for the first time its potential utility in delivering mRNA vaccines.”
Altamira Therapeutics (NASDAQ: CYTO) Stock Performance
CYTO stock surged 35.84% to close at $2.35 on Monday. The traders had exchanged hands with 62,807,936(62.80 million) shares compared to the average daily trading volume of 1.20 M. The stock has a market capitalization of $3.71 million.
Altamira Therapeutics CYTO CYTO shares CYTO stock CYTO stock news NASDAQ: CYTO
